These promising early results have prompted advancement to phase II trials.593 Given IRAK4’s involvement in various other autoimmune diseases,594 IRAK4 degraders hold significant potential for broadening therapeutic applications in clinical settings. The gene discussed is IRAK4; the disease is autoimmune disease.